Provectus
This person does not yet have a bio.Content by Provectus
| 6 min read
A
reprint of a commentary from our Cancer Research News site looking at three candidate drugs currently under investigation as intralesional agents for
melanoma treatment
| 6 min read
Despite past safety
concerns, enthusiasm for intralesional cancer therapies is waxing once again, with several companies advancing intralesional treatment candidates for
melanoma
Page 1 of 1 - 2 Total Items
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Overcoming barriers in gene therapy
Advanced gene editing, delivery, and analytical tools are driving better gene therapies.
A multiomic approach to profiling brain tumors
Probing the molecular drivers of brain metastasis reveals novel therapeutic targets.
Enhancing immune cell profiling with digital technologies
Software innovations help researchers decode immune complexity in cancer.
